View : 387 Download: 0

Full metadata record

DC Field Value Language
dc.contributor.author한운섭-
dc.contributor.author김광호-
dc.date.accessioned2016-08-28T11:08:10Z-
dc.date.available2016-08-28T11:08:10Z-
dc.date.issued1999-
dc.identifier.issn0008-543X-
dc.identifier.otherOAK-152-
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/218475-
dc.description.abstractBACKGROUND. Transforming growth factor-β1 (TGF-β1) acts as a potent inhibitor of cell growth and tumor progression but loss of this negative regulation can contribute to tumor development. Some studies have reported an association between disease progression and TGF-β1 expression in patients with colorectal carcinoma, but their results were not always consistent. METHODS. Serum levels of TGF-β1 were measured using an enzyme-linked immunoadsorbent assay in 121 consecutive patients with colorectal carcinoma and compared with TGF-β1 serum levels in 31 healthy volunteers. Serum levels of TGF-β1 also were measured in 50 patients who underwent curative surgical resection (part of the 121 preoperative patients) to compare their levels with preoperative serum levels of TGF-β1. RESULTS. Serum levels of TGF-β1 in patients with colorectal carcinoma (45 ± 15 ng/mL) (mean ± the standard deviation) were significantly higher than those in the healthy control group (32 ± 4 ng/mL) (P = 0.001). Serum levels of TGF-β1 increased with increasing tumor stage (P < 0.01). Serum levels of TGF-β1 were correlated significantly with depth of tumor invasion, lymph node metastasis, distant metastasis, and serum levels of carcinoembryonic antigen (CEA). Serum levels of TGF-β1 tended to increase with increasing CEA (correlation coefficient = 0.21; P < 0.05). The mean serum level of TGF-β1 in patients with colorectal carcinoma before surgery (45 ± 14 ng/mL) (n = 50) significantly decreased to 34 ± 7 ng/mL, which was within the normal range (32 ± 4 ng/mL), after curative surgical resection of the tumor (P = 0.0000). Serum levels of TGF- β1 after tumor resection decreased more significantly in patients with higher preoperative levels of TGF-β1 (from 53 ± 12 ng/mL to 36 ± 6 ng/mL) (n = 30). CONCLUSIONS. The results of the current study suggest that serum levels of TGF-β1 in colorectal carcinoma patients may be associated with disease progression and may be used as a biomarker in the management of colorectal carcinoma patients. The authors believe further studies with a large number of patients for a longer follow-up period are necessary to conclude whether serum levels of TGF-β1 carry significant clinical relevance. [See editorial on pages 517-9, this issue].-
dc.languageEnglish-
dc.titleElevated serum levels of transforming growth factor-β1 in patients with colorectal carcinoma: Its association with tumor progression and its significant decrease after curative surgical resection-
dc.typeArticle-
dc.relation.issue3-
dc.relation.volume85-
dc.relation.indexSCIE-
dc.relation.indexSCOPUS-
dc.relation.startpage554-
dc.relation.lastpage561-
dc.relation.journaltitleCancer-
dc.identifier.doi10.1002/(SICI)1097-0142(19990201)85:3&lt-
dc.identifier.doi554::AID-CNCR6&gt-
dc.identifier.doi3.0.CO-
dc.identifier.doi2-X-
dc.identifier.wosidWOS:000078390100006-
dc.identifier.scopusid2-s2.0-0006335227-
dc.author.googleShim K.S.-
dc.author.googleKim K.H.-
dc.author.googleHan W.S.-
dc.author.googlePark E.B.-
dc.contributor.scopusid한운섭(7401899962;24172227800)-
dc.contributor.scopusid김광호(57189050414)-
dc.date.modifydate20180329105812-
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE